PT-141 (Bremelanotide): Desire, Not Blood Flow

📅 July 20, 2026 ⏱️ 2 min read ✍️ Team TPS

PT-141 works on the brain, not on blood flow, which is precisely why it exists alongside the ED medications rather than competing with them.

What it is

PT-141 is bremelanotide, a melanocortin receptor agonist derived from the same research that produced Melanotan 2. The libido effect was noticed as a side effect of the tanning work and then developed deliberately.

Why the mechanism matters

PDE5 inhibitors like tadalafil act on blood flow. They help the mechanics of an erection but do nothing for desire.

PT-141 acts centrally on melanocortin receptors involved in sexual arousal. It addresses desire rather than plumbing, which makes it useful for a problem the PDE5 drugs simply do not treat, and it works in women as well as men, which those drugs largely do not.

The side effects are familiar

Because it shares MT2’s non-selective character, it shares its complaints: nausea most commonly, plus flushing and headache. Nausea is frequent enough to be considered typical rather than unusual.

Some pigmentation darkening is possible with repeated use for the same reason MT2 causes it, though PT-141 is far more selective in practice.

Blood pressure

Transient increases in blood pressure and reductions in heart rate are reported. That makes it a poor choice for anyone with uncontrolled hypertension or cardiovascular disease, and it is the reason the clinical version carries specific cautions.

Timing rather than dosing

PT-141 is used ahead of time rather than continuously, which is a different pattern from most things in this category. It is not something that builds up.

Where it fits

Where the problem is desire rather than function, or where PDE5 inhibitors have not helped because they were never addressing the actual issue. Not a replacement for investigating a persistent problem properly, low libido on cycle often traces to oestrogen or prolactin instead, which are cheap blood tests away. See cabergoline and prolactin and aromatase inhibitors compared.

Supplied for research purposes only.